Description
Disease Indications
Familial chylomicronemia syndrome (FCS)
Manufacturer
Akcea Therapeutics Ireland Limited
Usage
Subcutaneous
Medicine approved by
European Medical Agency (EMA)
Waylivra (volanesorsen)
$10,000.00
Waylivra (volanesorsen) is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and plasma triglycerides lowering therapy has been inadequate.
Additional information
| Package Single use pre-filled syringe | 285 mg in 1.5 mL |
|---|
Related products
-
Leqvio (inclisiran)
$2,000.00 Select options This product has multiple variants. The options may be chosen on the product page -
Isturisa (osilodrostat)
Price range: $1,000.00 through $5,000.00 Select options This product has multiple variants. The options may be chosen on the product page -
Zegalogue (dasiglucagon)
Price range: $300.00 through $600.00 Select options This product has multiple variants. The options may be chosen on the product page -
Ozempic (semaglutide)
$200.00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.